Kreshnik Zejnullahu
Impact in
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
Papers in
-
- Lung Cancer Treatments and Mutations 12
-
- PI3K/AKT/mTOR signaling in cancer 4
- Cancer therapeutics and mechanisms 3
- Protein Degradation and Inhibitors 1
- Co-authors
- Pasi A. Jänne (11 shared papers)Jeffrey A. Engelman (5 shared papers)Bruce E. Johnson (5 shared papers)James G. Christensen (4 shared papers)Andrew M. Rogers (3 shared papers)Lewis C. Cantley (3 shared papers)Xiao‐Jun Zhao (3 shared papers)Charles Lee (3 shared papers)
- Journals
- Cancer Research (5 papers)Journal of Thoracic Oncology (2 papers)Clinical Cancer Research (1 paper)Science (1 paper)New England Journal of Medicine (1 paper)
- Partner nations
- United StatesJapanIsrael
In The Last Decade
Kreshnik Zejnullahu
15 papers receiving 5.4k citations
Hit Papers
Peers
Comparison fields: 5 of 90
- Oncology 3.1k
- Pulmonary and Respiratory Medicine 3.2k
- Hepatology 520
- Cancer Research 956
- Molecular Biology 3.1k
Countries citing papers authored by Kreshnik Zejnullahu
This map shows the geographic impact of Kreshnik Zejnullahu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kreshnik Zejnullahu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kreshnik Zejnullahu more than expected).
Fields of papers citing papers by Kreshnik Zejnullahu
This network shows the impact of papers produced by Kreshnik Zejnullahu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kreshnik Zejnullahu. The network helps show where Kreshnik Zejnullahu may publish in the future.
Co-authors
The 25 scholars most cited alongside Kreshnik Zejnullahu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Hit paper breakdown → | 2007 | 3570 |
| 2 | PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib Hit paper breakdown → | 2007 | 598 |
| 3 | 2006 | 374 | |
| 4 | 2012 | 277 | |
| 5 | 2010 | 181 | |
| 6 | 2012 | 163 | |
| 7 | 2015 | 125 | |
| 8 | 2008 | 96 | |
| 9 | 2011 | 80 | |
| 10 | 2016 | 5 | |
| 11 | 2012 | 4 | |
| 12 | 2016 | 1 | |
| 13 | 2007 | 1 | |
| 14 | 2007 | 1 | |
| 15 | 2011 | 1 | |
| 16 | 2008 | 1 | |
| 17 | 2025 | 0 |
About Kreshnik Zejnullahu
Kreshnik Zejnullahu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Pathology and Forensic Medicine and Cancer Research, having authored 17 papers that have together received 5.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Cancer therapeutics and mechanisms (3 papers), Cancer Mechanisms and Therapy (2 papers), Protein Degradation and Inhibitors (1 paper) and Cancer Treatment and Pharmacology (1 paper). The work is most often cited by research in Oncology (3.1k citations), Pulmonary and Respiratory Medicine (3.2k citations), Hepatology (520 citations), Cancer Research (956 citations) and Molecular Biology (3.1k citations). Kreshnik Zejnullahu has collaborated with scholars based in United States, Japan and Israel. Frequent co-authors include Pasi A. Jänne, Jeffrey A. Engelman, Bruce E. Johnson, James G. Christensen, Andrew M. Rogers, Lewis C. Cantley, Xiao‐Jun Zhao, Charles Lee, Neal I. Lindeman and Federico Cappuzzo. Their work appears in journals such as Cancer Research, Journal of Thoracic Oncology, Clinical Cancer Research, Science and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.